Regeneration of tumor antigen-specific CTLs utilizing iPS technology.
Tumor immunotherapy, especially tumor antigen specific T cell therapy, is currently attracting attention. However, a critical issue still awaits resolution; it is difficult to efficiently expand tumor antigen-specific T cells. To solve this problem, we are now utilizing iPS cell technology. When iPS cells are established from tumor antigen specific T cells, T cells regenerated from these iPS cells are expected to express the same TCRs as the original T cells. In line with this concept, we succeeded in regenerating tumor antigen specific cytotoxic T cells. The regenerated T cells exhibited TCR specific killing activity comparable to that of the original cells, and were able to kill leukemia cells in an antigen-specific manner. We are currently endeavoring to apply this method clinically. In the future, we intend to establish an allogeneic transfusion system, in which various tumor antigen specific T-iPS cells from a wide range of HLA haplotype homozygous donors will be lined up as a "T-iPS cell bank", with the aim of making off-the-shelf tumor immunotherapy a reality.
Department of Immunology, Institute for Frontier Medical Science, Kyoto University.
Takuya
T
Maeda
Kyoko
K
Masuda
Hiroshi
H
Kawamoto
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D006239:Haplotypes; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000951:Antigens, Neoplasm; D015395:Histocompatibility Antigens Class I; D011948:Receptors, Antigen, T-Cell